NIH's Role In Sustaining the U.S. Economy 2021 Update Now Available here
UMR Urges House and Senate Leaders to Include NIH Funding in COVID Relief Package read here
UMR releases new fact sheets on COVID-19 and biomedical research. Read here
See how UMR members are aiding in the fight against the coronavirus here
A new episode of the Amazing Things Podcast is now available! Check it out here.

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

Turning the Tide on Ebola: A Conversation with NIAID’s Dr. Anthony Fauci & Regeneron’s Neil Stahl


NIAID’s Dr. Anthony Fauci
Regeneron Executive Vice President for Research and Development, Neil Stahl

In this episode of the Amazing Things Podcast, we talk to Dr. Anthony Fauci, director of NIH’s National Institute of Allergies and Infectious Diseases and Regeneron Pharmaceutical Executive Vice President for Research and Development Neil Stahl and how their organizations supported the effort to develop effective treatments for Ebola.

A major outbreak of the Ebola virus in West Africa from 2014–2016 infected tens of thousands and captured worldwide attention as it traveled across borders and even made its way to the United States. While rare, Ebola is particularly frightening as it has eluded effective treatment since it first appeared in 1976. Approximately half of those who contract it will die.


However, in August 2019, a multinational effort — spearheaded by the World Health Organization, the National Institutes of Health (NIH) and the Institut National de Recherche Biomédicale — turned the tide on Ebola. Critical to this effort was the research and drug development efforts of private sector companies and the NIH.